Michael Sean Flint

US Patent:

8557548, Oct 15, 2013

Filed:

Mar 22, 2013

Appl. No.:

13/848909

Inventors:

Robert G. K. Donald - South Orange NJ, US
Kathrin Ute Jansen - Allendale NJ, US
Michael James Flint - Decatur GA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

C12N 15/70
C12P 21/06

US Classification:

435 713, 435 691, 435 711, 43525233, 536 237

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20050209717, Sep 22, 2005

Filed:

Mar 7, 2005

Appl. No.:

11/073812

Inventors:

Michael Flint - Decatur GA, US
Rodney Grubbs - Brookville IN, US
James Hutchings - Toronto, CA

International Classification:

A63F013/00

US Classification:

700091000

Abstract:

A method and apparatus implemented on a computing device to generate competition data. An index value for each competitor is generated which provides for a comparative evaluation of competitors.

US Patent:

20120269841, Oct 25, 2012

Filed:

Apr 20, 2012

Appl. No.:

13/451631

Inventors:

Maninder K. Sidhu - New City NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G. K. Donald - South Orange NJ, US
Kathrin Ute Jansen - Allendale NJ, US
Narender K. Kalyan - Ridgewood NJ, US
Terri L. Mininni - New Windsor NY, US
Justin Keith Moran - Valley Cottage NY, US
Mark E. Ruppen - Garnerville NY, US
Michael James Flint - Decatur GA, US

Assignee:

WYETH LLC - Madison NJ

International Classification:

A61K 39/08
A61P 37/02
C07K 14/33

US Classification:

4241901, 530409

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20130330371, Dec 12, 2013

Filed:

Aug 19, 2013

Appl. No.:

13/970048

Inventors:

Maninder K. Sidhu - New City NY, US
Robert G. K. Donald - South Orange NJ, US
Kathrin Ute Jansen - Allendale NJ, US
Narender Kumar Kalyan - Ridgewood NJ, US
Justin Keith Moran - Valley Cottage NY, US
Mark E. Ruppen - Garnerville NY, US
Michael James Flint - Decatur GA, US

Assignee:

WYETH LLC - MADISON NJ

International Classification:

C12N 9/10
C12N 9/99

US Classification:

4241901, 435193, 435184

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

US Patent:

20210024903, Jan 28, 2021

Filed:

Jul 7, 2020

Appl. No.:

16/922952

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G. K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Kathrin Ute Jansen - New York NY, US
Maninder K. Sidhu - New City NY, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Garnerville NY, US
Weiqiang Sun - Morristown NJ, US

International Classification:

C12N 9/10
C07K 14/33
C12N 1/20

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing and in producing toxins.

US Patent:

20200254081, Aug 13, 2020

Filed:

Sep 14, 2018

Appl. No.:

16/647124

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Nicholas Randolph Everard Kitchin - Sandwich, GB
Justin Keith Moran - West Nyack NY, US
Louise Pedneault - New York NY, US
Michael W. Pride - Staten Island NY, US
Mark Edward Ruppen - Cresco PA, US
Christopher Frederick Webber - Sandwich, GB

International Classification:

A61K 39/08
A61K 9/19

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a toxoid A and/or a toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a infection. The method includes administering to the human an effective dose of a composition, which includes a toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against toxin A and/or toxin B is sustained.

US Patent:

20200165582, May 28, 2020

Filed:

Dec 5, 2019

Appl. No.:

16/704744

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Michael James Flint - Decatur GA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Kathrin Ute Jansen - New York NY, US
Maninder K. Sidhu - Bangor PA, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Cresco PA, US
Weiqiang Sun - Morristown NJ, US

International Classification:

C12N 9/10
C12N 1/20
C07K 14/33

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing and in producing toxins.

US Patent:

20200095290, Mar 26, 2020

Filed:

Dec 5, 2019

Appl. No.:

16/704777

Inventors:

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Robert G.K. Donald - South Orange NJ, US
Maninder K. Sidhu - Bangor PA, US
Narender Kumar Kalyan - Ridgewood NJ, US
Justin Keith Moran - West Nyack NY, US
Mark Edward Ruppen - Cresco PA, US
Michael James Flint - Decatur GA, US

International Classification:

C07K 14/33
C07K 16/12
C12N 15/74
C12N 9/10
C12N 9/99
A61K 39/08

Abstract:

In one aspect, the invention relates to an immunogenic composition that includes a mutant toxin A and/or a mutant toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.